Eichelbaum Ehrentraud J, Vesely Brian A, Alli Abdel A, Sun Ying, Gower William R, Vesely David L
Department of Internal Medicine, James A. Haley Veterans Medical Center, Tampa, FL 33612, USA.
Endocrine. 2006 Dec;30(3):325-32. doi: 10.1007/s12020-006-0011-6.
Four cardiac hormones, i.e., atrial natriuretic peptide, vessel dilator, long-acting natriuretic peptide, and kaliuretic peptide, which have anticancer effects, were evaluated for the first time on any endocrine cancer to determine if they have anticancer effects in an endocrine cancer. These four cardiac hormones were evaluated for their anticancer, DNA synthesis, and receptor status in human medullary thyroid cancer cells. There was a significant (p < 0.001) decrease in human medullary thyroid cancer cells with each 10-fold increase from 1 to 100 microM of the four cardiac hormones. There was an 81%, 68%, 71%, and 66% elimination within 24 h of medullary thyroid cancer cells secondary to vessel dilator, kaliuretic peptide, atrial natriuretic peptide, and long-acting natriuretic peptide, respectively (p < 0.0001). Three days after treatment with these peptide hormones, there was no proliferation of the medullary thyroid cancer cells. These cardiac hormones decreased DNA synthesis in the medullary thyroid cells from 65% to 84% (p < 0.0001). Western blots revealed natriuretic peptide receptors-A and -C were present in human medullary thyroid cancer cells. These results indicate the four cardiac hormones have potent anticancer effects by eliminating up to 82% of human medullary thyroid carcinoma cells within 24 h of treatment.
首次对四种具有抗癌作用的心脏激素，即心钠素、血管舒张素、长效利钠肽和利钾肽，在任何内分泌癌上进行评估，以确定它们在内分泌癌中是否具有抗癌作用。对这四种心脏激素在人甲状腺髓样癌细胞中的抗癌、DNA合成及受体状态进行了评估。随着四种心脏激素浓度从1微摩尔每升增加到100微摩尔每升，每次增加10倍，人甲状腺髓样癌细胞数量显著减少（p < 0.001）。分别在24小时内，血管舒张素、利钾肽、心钠素和长效利钠肽使甲状腺髓样癌细胞数量分别减少81%、68%、71%和66%（p < 0.0001）。用这些肽类激素治疗三天后，甲状腺髓样癌细胞没有增殖。这些心脏激素使甲状腺髓样细胞中的DNA合成减少65%至84%（p < 0.0001）。蛋白质免疫印迹显示人甲状腺髓样癌细胞中存在利钠肽受体-A和-C。这些结果表明，这四种心脏激素在治疗24小时内可消除高达82%的人甲状腺髓样癌细胞，具有强大的抗癌作用。
